Significance of neuropilin-1 expression in acute myeloid leukemia;Ciddi, dirençli,öldürücü, kazanılmış aplastik aneminin klinik seyrine e uygulamasının katkısı

Turkish Journal of Hematology

Volumn 30, Issue 3, 2013, Pages 300-306

  Sallam, Tarif H ^a   Eldin El Telbany, Manal A Shams ^a   Mahmoud, Hanan M ^a   Iskander, Mutea A ^b  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b SANA A UNIVERSITY   (Yemen)

Author keywords

Acute myeloid leukemia; Neuropilin 1

Indexed keywords

CD14 ANTIGEN; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; MESSENGER RNA; MONOCLONAL ANTIBODY; NEUROPILIN 1; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW EXAMINATION; CANCER PROGNOSIS; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; FEMALE; FLOW CYTOMETRY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LABORATORY TEST; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 84883757811     PISSN: 13007777     EISSN: 13085263     Source Type: Journal    
DOI: 10.4274/Tjh.2011.0005     Document Type: Article

References (19)

1. Vales A, Kondo R, Aichberger KJ, Mayerhofer M, Kainz B, Sperr WR, Sillaber C, Jäger U, Valent P. Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2. Leuk Lymphoma 2007;48:1997-2007.
2. Latil A, Bièche I, Pesche S, Valéri A, Fournier G, Cussenot O, Lidereau R. VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms. Int J Cancer 2000;89:167-171.
3. Lu L, Zhang L, Xiao Z, Lu S, Yang R, Han ZC. Neuropilin-1 in acute myeloid leukemia: expression and role in proliferation and migration of leukemia cells. Leuk Lymphoma 2008;49:331-338.
4. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
5. Zhou J, Mauerer K, Farina L, Gribben JG. The role of the tumor microenvironment in hematological malignancies and implication for therapy. Front Biosci 2005;10:1581-1596.
6. Zacchigna S, Pattarini L, Zentilin L, Moimas S, Carrer A, Sinigaglia M, Arsic N, Tafuro S, Sinagra G, Giacca M. Bone marrow cells recruited through the neuropilin-1 receptor promote arterial formation at the sites of adult neoangiogenesis in mice. J Clin Invest 2008;118:2062-2075.
7. Schuch G, Machluf M, Bartsch G Jr, Nomi M, Richard H, Atala A, Soker S. In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. Blood 2002;100:4622-4628.
8. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005;106:1154-1163.
9. Kreuter M, Steins M, Woelke K, Buechner T, Berdel WE, Mesters RM. Downregulation of neuropilin-1 in patients with acute myeloid leukemia treated with thalidomide. Eur J Haematol 2007;79:392-397.
10. Staton CA, Kumar I, Reed MW, Brown NJ. Neuropilins in physiological and pathological angiogenesis. J Pathol 2007;212:237-248.
11. Staber PB, Linkesch W, Zauner D, Beham-Schmid C, Guelly C, Schauer S, Sill H, Hoefler G. Common alterations in gene expression and increased proliferation in recurrent acute myeloid leukemia. Oncogene 2004;23:894-904.
12. Bradstock K, Matthews J, Benson E, Page F, Bishop J. Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group. Blood 1994;84:1220-1225.
13. Wimazal F, Sperr WR, Kundi M, Vales A, Fonatsch C, Thalhammer-Scherrer R, Schwarzinger I, Valent P. Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes. Ann Oncol 2008;19:970-976.
14. Webber BA, Cushing MM, Li S. Prognostic significance of flow cytometric immunophenotyping in acute myeloid leukemia. Int J Clin Exp Pathol 2008;1:124-133.
15. Younan S, Elhoseiny S, Hammam A, Gawdat R, El-Wakil M, Fawzy M. Role of neuropilin-1 and its expression in Egyptian acute myeloid and acute lymphoid leukemia patients. Leuk Res 2012;36:169-173.
16. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-974.
17. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
18. Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 2006;33:26-34.
19. Pan Q, Chanthery Y, Liang WC, Stawicki S, Mak J, Rathore N, Tong RK, Kowalski J, Yee SF, Pacheco G, Ross S, Cheng Z, Le Couter J, Plowman G, Peale F, Koch AW, Wu Y, Bagri A, Tessier-Lavigne M, Watts RJ. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 2007;11:53-67.